NATCO Pharma receives USFDA tentative approval for Trabectedin, generic for Yondelis

18 Aug 2022 , 09:16 AM

NATCO Pharma Limited has announced to the stock exchanges that the U.S. Food and Drug Administration has granted tentative approval to its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis ) for the 1 mg/vial presentation.

According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market, the company said in a regulatory filing.

At around 9:16 AM, Natco Pharma Ltd was trading at Rs663.50 per share up by Rs12.2 or 1.87% from its previous closing of Rs651.30 per share on the BSE.